Heather Feigelson to Case-Control Studies
This is a "connection" page, showing publications Heather Feigelson has written about Case-Control Studies.
Connection Strength
0.852
-
Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Aug; 107(8).
Score: 0.102
-
No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2553-7.
Score: 0.068
-
Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jun; 15(6):1236-7.
Score: 0.055
-
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 2006 Feb 15; 66(4):2468-75.
Score: 0.053
-
No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):1084-5.
Score: 0.048
-
Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. 2002 Sep; 17(5):445-6; author reply 447-8.
Score: 0.042
-
Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 2001 Jan 15; 61(2):785-9.
Score: 0.038
-
Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000; 2(4):277-82.
Score: 0.036
-
Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
Score: 0.029
-
A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997 Mar 15; 57(6):1063-5.
Score: 0.029
-
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013 Apr; 45(4):392-8, 398e1-2.
Score: 0.022
-
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30; 43(12):1210-4.
Score: 0.020
-
Fine mapping of 14q24.1 breast cancer susceptibility locus. Hum Genet. 2012 Mar; 131(3):479-90.
Score: 0.020
-
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 01; 20(19):3867-75.
Score: 0.019
-
Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet. 2011 Jul 15; 20(14):2869-78.
Score: 0.019
-
Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet. 2011 Jun; 129(6):675-85.
Score: 0.019
-
A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep; 95(9):E121-7.
Score: 0.018
-
Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93.
Score: 0.018
-
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res. 2010 Mar 15; 70(6):2389-96.
Score: 0.018
-
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010 Mar; 31(3):455-61.
Score: 0.017
-
CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2734-44.
Score: 0.017
-
Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet. 2009 Oct 01; 18(19):3749-57.
Score: 0.017
-
Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):297-305.
Score: 0.016
-
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008 Sep; 40(9):1032-4; author reply 1035-6.
Score: 0.016
-
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008 Mar; 40(3):310-5.
Score: 0.015
-
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1973-81.
Score: 0.015
-
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007 Apr 01; 67(7):2951-6.
Score: 0.014
-
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007 Mar 01; 67(5):1893-7.
Score: 0.014
-
Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007; 9(1):R9.
Score: 0.014
-
A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005; 7(6):R1168-73.
Score: 0.013
-
Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 2001 Feb 01; 61(3):848-9.
Score: 0.009